Heart failure drug finerenone under Real-World safety watch in korea

NCT ID NCT07379840

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study observes 300 adults in South Korea with chronic heart failure who are prescribed finerenone as part of their usual care. Researchers will track side effects and treatment satisfaction over one year. The goal is to see how safe and effective finerenone is in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: finerenone
What this could lead to: If successful, this study could confirm that finerenone is safe and effective for South Korean patients with chronic heart failure.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only tracks routine care, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEART FAILURE

Contacts and locations

Locations

Many Locations
RECRUITING

Multiple Locations, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.